KEYNOTE-013 Phase 1b trial

June 20, 2018

Keytruda Conditionally Approved in US for Primary Mediastinal B-cell Lymphoma

News

The U.S. Food and Drug Administration has granted accelerated approval to Keytruda (pembrolizumab) for the treatment of relapsed or refractory primary mediastinal large B-cell lymphoma (PMBCL), making it the first anti-PD-1 therapy ... Read more

December 15, 2017December 15, 2017

FDA Reviews Application for Keytruda in Mediastinal B-cell Lymphoma

News

The U.S. Food and Drug Administration (FDA) agreed to review Merck’s application to add relapsed or refractory primary mediastinal large B-cell lymphoma (PMBCL) to the list of cancers treated with ... Read more

May 8, 2017May 8, 2017

Merck’s Keytruda Therapy for Certain Classical Hodgkin Lymphoma Patients Wins European Approval

News

The European Commission has approved the immune checkpoint inhibitor Keytruda (pembrolizumab) to treat certain Hodgkin lymphoma patients in 31 European countries, Merck announced. The approval applies to patients with relapsed or refractory classical ... Read more

December 13, 2016December 13, 2016

FDA Giving Priority Review to Keytruda as Possible Treatment for Classical Hodgkin’s Lymphoma

News

The U.S. Food and Drug Administration has accepted for review a supplemental Biologics Licence Application (sBLA) seeking the approval of Keytruda (pembrulizumab) for the treatment of patients with refractory classical Hodgkin’s ... Read more